Tag - Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Ziad2022-11-25T13:59:44-05:00Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held...

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Ziad2022-11-25T13:59:45-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimer’s. AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating...

Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors

Ziad2022-11-25T14:00:10-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced today that Christine Gallagher has joined the company’s Board of Directors. Ms. Gallagher has over 30 years of experience as an investment banker focused on the life sciences industry. She is currently Managing Director, Equity Capital Markets at Truist Securities (formerly SunTrust Robinson Humphrey) where she is directly responsible for leading the planning, structuring and execution of equity capital raises for...

CT Biotech Firm Working Drug to Treat Stroke, Brain Injuries

Ziad2022-11-25T14:00:10-05:00Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Last week, Astrocyte put out word that Stroke, a peer-reviewed journal, had published the results of preclinical studies of the drug, known for now as AST-004. The lack of available treatments for stroke is a major unmet medical need, one that could qualify Astrocyte’s drug development...

Groton biotech firm working on much-needed drug to treat stroke, brain injuries

Ziad2022-11-25T14:00:10-05:00A small drug development company that moved its headquarters from Cambridge, Mass., to the BioCT Innovations Commons on Shennecossett Road last year is aiming to have a huge impact on the treatment of strokes and brain injuries. Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Read more >>

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

Ziad2022-11-25T14:00:11-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. The manuscript describes the results of pre-clinical studies using AST-004, Astrocyte’s lead drug candidate, for the treatment of stroke. Read more >>

San Antonio researchers developing brain injury treatment

Ziad2022-11-25T14:00:11-05:00Research that began in San Antonio could soon produce a first-of-its-kind treatment for traumatic brain injuries, like concussions and strokes. The drug, which scientists hope to eventually administer as a pill, stimulates support cells responsible for cleaning up messes in the brain. These "astrocytes" are responsible for maintaining the environment in which nerve cells operate. "We found a mechanism with which you could increase the energy production of an astrocyte," said Dr. Jim Lechleiter, professor of cell systems and anatomy...

Brain injury therapy advancing toward human studies

Ziad2022-11-25T14:00:11-05:00Research that began at The University of Texas Health Science Center at San Antonio 15 years ago is nearing a significant milestone: human testing of an intravenous (IV) drug to treat brain injuries such as concussion and stroke. The implications are enormous. A therapy for soldiers on the battlefield, car crash victims, concussed football players and people who suffer strokes could ease the pain and suffering of thousands worldwide daily and prevent debilitating long-term effects of traumatic brain injury. Astrocyte Pharmaceuticals is...

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Ziad2022-11-25T14:00:12-05:00 Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the granting of a $3.0M award from the Medical Technology Enterprise Consortium (MTEC). Read more >> 

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Ziad2022-11-25T14:00:12-05:00 Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation. Read more >>